UCB agreed to license Antengene’s ATG‑201, a CD19×CD3 bispecific T‑cell engager (TCE), in a deal that includes $80 million upfront and more than $1.1 billion in potential development and commercial milestones. Antengene will complete first‑in‑human phase I studies before transferring global rights to UCB. UCB described the acquisition as its entry into the TCE modality for immunology, citing ATG‑201’s preclinical activity against B‑cell driven diseases. Antengene’s AnTenGager platform produced the asset; preclinical data show bispecific engagement of T and B cells through CD3 and CD19. TCEs recruit a patient’s T cells to eliminate target cells and are an emerging class in oncology and, increasingly, autoimmune disease. The deal signals big‑pharma appetite for next‑generation bispecific modalities outside oncology and adds firepower to UCB’s immunology pipeline.